Form 8-K - Current report:
SEC Accession No. 0001104659-25-057066
Filing Date
2025-06-06
Accepted
2025-06-06 08:05:21
Documents
15
Period of Report
2025-06-05
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2517205d1_8k.htm   iXBRL 8-K 49055
2 EXHIBIT 10.1 tm2517205d1_ex10-1.htm EX-10.1 7586
3 EXHIBIT 99.1 tm2517205d1_ex99-1.htm EX-99.1 10676
7 GRAPHIC tm2517205d1_ex99-1img001.jpg GRAPHIC 6084
  Complete submission text file 0001104659-25-057066.txt   250389

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA cldx-20250605.xsd EX-101.SCH 3047
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE cldx-20250605_lab.xml EX-101.LAB 34239
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE cldx-20250605_pre.xml EX-101.PRE 22380
17 EXTRACTED XBRL INSTANCE DOCUMENT tm2517205d1_8k_htm.xml XML 3596
Mailing Address 53 FRONTAGE ROAD SUITE 220 HAMPTON NJ 08827
Business Address 53 FRONTAGE ROAD SUITE 220 HAMPTON NJ 08827 908-200-7500
Celldex Therapeutics, Inc. (Filer) CIK: 0000744218 (see all company filings)

EIN.: 133191702 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-15006 | Film No.: 251028926
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)